Pay-for-performance schemes: Should optimal prices vary across system and clinical quality indicators?

S. Grepperud
{"title":"Pay-for-performance schemes: Should optimal prices vary across system and clinical quality indicators?","authors":"S. Grepperud","doi":"10.5617/NJHE.5932","DOIUrl":null,"url":null,"abstract":"Quality indicators are classified into system or clinical quality indicators. Typically, different levels of an organization steer each of the two types of indicators. Decentralized levels control clinical indicators (blood pressure, blood sugar etc.) while centralized levels control system indicators (waiting time, electronic health records etc.). In this paper we examine optimal pay-for-performance schemes for the two indicators by considering a model consisting of hierarchy of principal-agent interactions where pay-for-performance rewards are distributed to the centralized level (unit of accountability). We find that the optimal pay-for-performance price depends on factors such as the degree and distribution of altruistic preferences, quality costs, the marginal cost of public funds, and the interdependence between the quality variables. The optimal price should differ for system and clinical indicators both when an internal incentive system is in place and when this is not the case. The optimal price for clinical indicators is to reflect the centralized levels’ ability to steer the decentralized level - the type of internal contract that exists between the two levels of the organization. The optimal price for system indicators is independent of the type of internal contract since such indicators are under the control of the unit of accountability. Finally, it is shown that rewarding organizations on the basis of clinical quality indicators can be optimal also when such incentives are not transmitted to the decentralized level of the organization. This conclusion is the result of the indirect effects that non-incentivized variables (system indicators) might have on the incentivized ones (clinical indicators).Published: Online May 2019. ","PeriodicalId":30931,"journal":{"name":"Nordic Journal of Health Economics","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nordic Journal of Health Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5617/NJHE.5932","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Quality indicators are classified into system or clinical quality indicators. Typically, different levels of an organization steer each of the two types of indicators. Decentralized levels control clinical indicators (blood pressure, blood sugar etc.) while centralized levels control system indicators (waiting time, electronic health records etc.). In this paper we examine optimal pay-for-performance schemes for the two indicators by considering a model consisting of hierarchy of principal-agent interactions where pay-for-performance rewards are distributed to the centralized level (unit of accountability). We find that the optimal pay-for-performance price depends on factors such as the degree and distribution of altruistic preferences, quality costs, the marginal cost of public funds, and the interdependence between the quality variables. The optimal price should differ for system and clinical indicators both when an internal incentive system is in place and when this is not the case. The optimal price for clinical indicators is to reflect the centralized levels’ ability to steer the decentralized level - the type of internal contract that exists between the two levels of the organization. The optimal price for system indicators is independent of the type of internal contract since such indicators are under the control of the unit of accountability. Finally, it is shown that rewarding organizations on the basis of clinical quality indicators can be optimal also when such incentives are not transmitted to the decentralized level of the organization. This conclusion is the result of the indirect effects that non-incentivized variables (system indicators) might have on the incentivized ones (clinical indicators).Published: Online May 2019. 
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
按绩效付费方案:最优价格应因系统和临床质量指标而异吗?
质量指标分为系统质量指标和临床质量指标。通常,一个组织的不同层次会控制这两种类型的指标。分散级别控制临床指标(血压、血糖等),集中级别控制系统指标(等待时间、电子健康记录等)。在本文中,我们通过考虑一个由委托代理相互作用的层次结构组成的模型来检验这两个指标的最优绩效薪酬方案,其中绩效薪酬奖励分配到中央层面(责任单位)。我们发现,最优绩效薪酬价格取决于利他偏好的程度和分布、质量成本、公共资金的边际成本以及质量变量之间的相互依赖等因素。在有内部激励机制和没有内部激励机制的情况下,系统和临床指标的最优价格应该有所不同。临床指标的最优价格是反映集中层面引导分散层面的能力——组织两层之间存在的一种内部契约。系统指标的最优价格与内部合同的类型无关,因为这些指标是在问责单位的控制之下。最后,研究表明,当这种激励不传递到组织的分散层面时,基于临床质量指标的奖励组织也是最优的。这一结论是非激励变量(系统指标)可能对激励变量(临床指标)产生间接影响的结果。2019年5月在线发布。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
1
审稿时长
51 weeks
期刊最新文献
GP Recruitment and retention in the Nordic countries The role of occupational health care in ambulatory health care in Finland Work pressure and job dissatisfaction: Challenges in Danish general practice Using matching methods to account for selection bias in Norway’s Primary Care Teams (PCT) pilot Quality of Life in the Swedish General Population During COVID-19 - Based on pre- and post-pandemic outbreak measurement
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1